Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 6/20 | 0.60 |
| ▸ | PLK1 | P53350 | 1/20 | 0.54 |
| ▸ | AKT1 | P31749 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.52 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.52 |
| ▸ | EIF2AK2 | P19525 | 2/20 | 0.49 |
| ▸ | CLK1 | P49759 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.48 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
| ▸ | CDK4 | P11802 | 2/20 | 0.47 |
| ▸ | IKBKB | O14920 | 2/20 | 0.47 |
| ▸ | DKK1 | O94907 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6799823 | 0.86 | CDK2 (0.65) | CDK2PLK1PIK3CAPIK3CBPIK3CG | |
| SCHEMBL6795561 | 0.80 | CCNB2 (0.54) | CDK2PIK3CAPIK3CBPIK3CGEIF2AK2 | |
| SCHEMBL6800610 | 0.79 | PLK1 (0.56) | CDK2PLK1AKT1KDRPTK2 | |
| SCHEMBL14378895 | 0.78 | CDK2 (0.70) | CDK2PLK1AKT1KDRPTK2 | |
| SCHEMBL6157084 | 0.75 | CDK2 (1.00) | CDK2PLK1CDK4AURKACDK1 | |
| SCHEMBL27445357 | 0.74 | PIK3CG (0.57) | CDK2PLK1AKT1KDRPTK2 | |
| Ammonia Solution, Strong SCHEMBL3414338 | 0.74 | EIF2AK2 (0.57) | CDK2PLK1AKT1KDRPTK2 | |
| SCHEMBL2073680 | 0.73 | CDK2 (0.78) | CDK2PLK1AKT1KDRPTK2 | |
| SCHEMBL4384443 | 0.73 | SYK (0.70) | CDK2PLK1AKT1KDRPTK2 | |
| SCHEMBL2288706 | 0.72 | CDK2 (0.78) | CDK2PLK1KDRPTK2DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6699854-B2 | 2-SUBSTITUTED 4-HETEROARYL- PYRIMIDINES, INHIBITORS OF CYCLIN-DEPENDENT KINASES (CDKS) | CYCLACEL LIMITED (GB) | 2004-03-02 | — | — | US | claimed |
| US-20030149057-A1 | Anti-cancer compounds | CYCLACEL LIMITED (GB) | 2003-08-07 | — | — | US | claimed |
| EP-1274705-A1 | 2-SUBSTITUTED 4-HETEROARYL-PYRIMIDINES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2003-01-15 | — | — | EP | claimed |
| US-20020019404-A1 | Anti-cancer compounds | CYCLACEL LIMITED (GB) | 2002-02-14 | — | — | US | claimed |
| WO-2001072745-A1 | 2-SUBSTITUTED 4-HETEROARYL-PYRIMIDINES AND THEIR USE IN THE TREATMETN OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2001-10-04 | — | — | WO | claimed |
| US-6699854-B2 | 2-SUBSTITUTED 4-HETEROARYL- PYRIMIDINES, INHIBITORS OF CYCLIN-DEPENDENT KINASES (CDKS) | CYCLACEL LIMITED (GB) | 2004-03-02 | — | — | US | disclosed |
| US-20030149057-A1 | Anti-cancer compounds | CYCLACEL LIMITED (GB) | 2003-08-07 | — | — | US | disclosed |
| US-6531479-B2 | Anticancer agents, skin disorders | CYCLACEL LIMITED (GB) | 2003-03-11 | — | — | US | disclosed |
| EP-1274705-A1 | 2-SUBSTITUTED 4-HETEROARYL-PYRIMIDINES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2003-01-15 | — | — | EP | disclosed |
| US-20020019404-A1 | Anti-cancer compounds | CYCLACEL LIMITED (GB) | 2002-02-14 | — | — | US | disclosed |
| WO-2001072745-A1 | 2-SUBSTITUTED 4-HETEROARYL-PYRIMIDINES AND THEIR USE IN THE TREATMETN OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019404-A1 | Anti-cancer compounds | CDK3, CDK2, CDK4 | CDK2 2/4885PLK1 53/4885AKT1 520/4885 |
| US-20030149057-A1 | Anti-cancer compounds | CDK3, CDK2, CDK4 | CDK2 2/4885PLK1 53/4885AKT1 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.